#Immuno Oncology Assays Market Report

[soumyafwr]

https://twikkers.nl/blogs/175011/Immuno-Oncology-Assays-Market-Size-Share-and-Forecast-2031

Immuno Oncology Assays Market Size, Share and Forecast 2031

[yashvicmi01]

Global Immuno-Oncology Assays Market Is Estimated To Witness High Growth Owing To Increasing Adoption of Immuno-Oncology Therapies

The global immuno-oncology assays market is estimated to be valued at US$3,718.5 million in 2021 and is expected to exhibit a CAGR of 10.7% over the forecast period 2022-2028, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:

The immuno-oncology assays market refers to the market for diagnostic assays used in the field of immuno-oncology. These assays are used to measure the immune response to cancer cells and aid in the development of immunotherapies. The products associated with this market include immunoassays, flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS) platforms.

B) Market Dynamics:

The immuno-oncology assays market is driven by two main factors:

1. Increasing adoption of immuno-oncology therapies: The demand for immuno-oncology assays is expected to grow significantly due to the increasing adoption of immuno-oncology therapies. These therapies have shown promising results in the treatment of various types of cancers, leading to a rise in their utilization.

2. Technological advancements: Advancements in immuno-oncology assays, such as the development of high-throughput platforms and multiplexing assays, are fueling market growth. These advancements enable the detection and analysis of multiple biomarkers simultaneously, improving the accuracy and efficiency of cancer diagnosis and treatment.

C) Segment Analysis:

The Immuno-Oncology Assays Market can be segmented based on product type, application, and end-user. Among these, the immunoassay segment is expected to dominate the market due to its wide range of applications and advantages such as high sensitivity and specificity. On the basis of applications, the research segment is anticipated to hold a significant market share, as immuno-oncology assays play a crucial role in research activities related to cancer immunotherapy.

D) PEST Analysis:

Political: Government initiatives to promote the development and adoption of immunotherapies can have a positive impact on the immuno-oncology assays market.

Economic: The increasing healthcare expenditure and growing investments in research and development activities are driving market growth.

Social: The rising prevalence of cancer and the growing awareness about immuno-oncology therapies among patients and healthcare professionals are contributing to market growth.

Technological: Continuous advancements in technologies such as NGS and multiplexing assays are opening new opportunities in the immuno-oncology assays market.

E) Key Takeaways:

The global immuno-oncology assays market is expected to witness high growth, exhibiting a CAGR of 10.7% over the forecast period, due to increasing adoption of immuno-oncology therapies.

North America is anticipated to dominate the market, owing to the presence of key market players and robust healthcare infrastructure.

Key players operating in the global immuno-oncology assays market include Charles River, Roche, Illumina, and Agilent Technologies, Inc.

In conclusion, the global immuno-oncology assays market is poised for significant growth in the coming years. The increasing adoption of immuno-oncology therapies and advancements in technology are driving market growth. The research segment is expected to witness high demand, while North America is projected to be the dominant region. Key players in the market are focused on research and development activities to stay competitive and cater to the growing demand for immuno-oncology assays.

[impossibledeanmakerwombat]

Biosimulation Market Current and Future Trends, Leading Players, Industry Segments and Regional Forecast to 2023 to 2032 | Says FMI

The Global Biosimulation Market according to a recent market study by Future Market Insights, was valued at US$ 2.6 billion in 2021 and is predicted to grow to US$ 20.9 billion by 2032. According to the report’s conclusions, biosimulation software will continue to be crucial for the market because it will account for the majority of sales. Software biosimulation will give the trials better and more effective findings, and there are many different types of software accessible for different types of research and application. From 2015 through 2021, the software segment’s revenue increased at a CAGR of 14.3%.

Revenue through Drug Development to Continue being growth Axis For Biosimulation Market

Pharmaceutical companies use biosimulation for drug development.  During a drug, development process biosimulation helps to identify the possible effects that the drug can have on a patient. The market through the drug development segment recorded a CAGR of 16.3% during 2015-2021.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16031

Biosimulation Market: Competition Insights

The key companies operating in the biosimulation market include Certara, Dassault Systemes, Advanced Chemistry Development, Simulation Plus Inc., Schrodinger, Inc., Chemical Computing Group, Physiomics Plc, Rosa & Co. LLC, BioSimulation Consulting Inc., Genedata AG, Instem Group of Companies, PPD, Inc., Insilico Biotechnology AG,  Rhenovia Pharma, LeadInvent Technologies, Nuventra Pharma, and In Silico  Biosciences.

Some of the recent developments by key providers of biosimulation are as follows:

In June 2022, Certara announced its new version of Biosimulation software for the progress of Novel Biologics. The new version includes Immunogenicity (IG), Immuno-Oncology (IO), and Vaccine simulators to understand and predict how drugs work and point out the key questions in the development of novel biologic therapies.

In June 2022, Genedata AG announced that Syros Pharmaceuticals has chosen Genedata AG’s Genedata Profiler as its data integration and investigative platform to accelerate its translational research strategy.

In March 2022, Advanced Chemistry labs announced that Pharmaron Inc. has chosen its NMR processing and interpretation software.

In March 2022, Simulation Plus, Inc. released its Membrane Plus 3.0 software. The new software includes improved data handling and simulation performance for in vitro-in vivo for extrapolation (IVIVE) for permeability, skin penetration, and release assay systems.

In February 2022, the US Food and Drug Administration (FDA) approved the license for Certara’s Immunogenicity (IG) stimulator to research and assess immunogenicity in protein-based remedies.

In February 2022, Physiomics Plc updated a new agreement with ValiRx plc. According to the new agreement, ValiRx will be able to use Physiomics Plc’s latest version of its Virtual Tumour technology. Physiomics Plc will also help ValiRx in modeling the use of VAL201 peptide in endometriosis (VAL301) and Coronavirus (BC201).

Limited time Offer, Get Customization @  https://www.futuremarketinsights.com/customization-available/rep-gb-16031

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Biosimulation Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights by Product Type (Services (In-house services, Contract services), Software), by Deployment mode (Drug Development, Drug Discovery, Other Applications), by End-use (Pharmaceutical & Biotechnology Companies, CROs, Regulatory Authorities, Academic Research Institutions), across five regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).

Key Segments Covered in Biosimulation Industry Survey

Biosimulation Market by Product Type:

Services

In-house services

Contract services

Software

Biosimulation Market by Deployment Mode:

Drug Development

Drug Discovery

Other Applications

Biosimulation Market by End-use:

Pharmaceutical &Biotechnology Companies

CROs

Regulatory Authorities

Academic Research Instituitons

Full Report @ https://www.futuremarketinsights.com/reports/biosimulation-market

[chemicaltech]

immune-oncology assay  Market worth USD 14.1 billion by 2031

The global immune-oncology assay market was valued at USD 4.2 billion in 2021 and it is anticipated to grow further up to USD 14.1 billion by 2031, at a CAGR of 12.9% during the forecast period.

One kind of immunoassay that is mostly used to diagnose cancer is the immuno-oncology assay. It is a process that profiles different analytes by simultaneously detecting and measuring them, including proteins, biomolecules, growth factors, cytokines, and chemokines. This method primarily targets and eliminates cancer cells using the body’s natural defensive mechanism. This assay is used for in vitro research to investigate the complex tumor microenvironment, the dynamic interactions between cancer cells and immune cells, and the perception of immunoreactivity in a variety of cell-based assays to determine the mode of action.

Get Sample Here – https://www.globalinsightservices.com/request-sample/GIS10299

Major Players in the Global Immuno-Oncology Assay Market

The key players studied in the market are Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Illumina, Inc. (US), NanoString Technologies, Inc. (US), Sartorius AG (Germany), HTG Molecular Diagnostics, Inc. (US), QIAGEN N.V. (Netherlands), Merck Millipore (US), PerkinElmer, Inc. (US), Abbott Laboratories, Inc. (US), Guardant Health, Inc. (US), and bioMérieux SA (France) among others.

Global Immuno-Oncology Assay Market

By Product & Services

  Consumables

Instruments

Software & Services

By Technology

  PCR

Immunoassay

NGS

ISH

Flow Cytometry

  Market Trends and Drivers

As a multi-stage carcinogenesis process involving numerous molecular pathway events, cancer is a complex illness that arises. So, the diagnosis, prognosis, and treatment of cancer are all accompanied with a number of challenges. In this aspect, a single marker is not useful due to the complexity of cancer. Each cancer also differs from other cancer kinds in terms of its molecular profile. As a result, the use of immuno-oncology assays has proved crucial for comprehending cancer signatures and creating individualized treatments. Over the past few years, cancer has become more commonplace across the globe. In 2018, there were 9.6 million fatalities due to cancer, which has overtaken all other causes of mortality in the world. GLOBOCAN predicts that by 2040, there would be over 30 million new instances of cancer, up from 18 million in 2018. Africa, Asia, Central and South America account for more than 60% of all new cancer cases, and these regions also account for 70% of all cancer-related fatalities worldwide. As a result, there is a need for considerable research to be done for cancer detection and therapy, and immuno-oncology assays play a significant role in this study.

  With Global Insight Services, you receive:

·         10-year forecast to help you make strategic decisions

·         In-depth segmentation which can be customized as per your requirements

·         Free consultation with lead analyst of the report

·         Excel data pack included with all report purchases

·         Robust and transparent research methodology

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm

headquartered in Delaware, US. We are committed to providing our clients

with highest quality data, analysis, and tools to meet all their market research

needs. With GIS, you can be assured of the quality of the deliverables, robust

and transparent research methodology, and superior service.

  Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1-833-761-1700

[rohit890]

Immuno-Oncology Assay Market Competition from Opponents, Dynamics, Demand and Risk to 20231

Market Overview

The global immune-oncology assay market was valued at USD 4.2 billion in 2021 and it is anticipated to grow further up to USD 14.1 billion by 2031, at a CAGR of 12.9% during the forecast period.

One kind of immunoassay that is mostly used to diagnose cancer is the immuno-oncology assay. It is a process that profiles different analytes by simultaneously detecting and measuring them, including proteins, biomolecules, growth factors, cytokines, and chemokines. This method primarily targets and eliminates cancer cells using the body’s natural defensive mechanism. This assay is used for in vitro research to investigate the complex tumor microenvironment, the dynamic interactions between cancer cells and immune cells, and the perception of immunoreactivity in a variety of cell-based assays to determine the mode of action.

View Detailed Report Description: https://www.globalinsightservices.com/reports/immuno-oncology-assays-market/

Market Dynamics

As a multi-stage carcinogenesis process involving numerous molecular pathway events, cancer is a complex illness that arises. So, the diagnosis, prognosis, and treatment of cancer are all accompanied with a number of challenges. In this aspect, a single marker is not useful due to the complexity of cancer. Each cancer also differs from other cancer kinds in terms of its molecular profile. As a result, the use of immuno-oncology assays has proved crucial for comprehending cancer signatures and creating individualized treatments. Over the past few years, cancer has become more commonplace across the globe. In 2018, there were 9.6 million fatalities due to cancer, which has overtaken all other causes of mortality in the world. GLOBOCAN predicts that by 2040, there would be over 30 million new instances of cancer, up from 18 million in 2018. Africa, Asia, Central and South America account for more than 60% of all new cancer cases, and these regions also account for 70% of all cancer-related fatalities worldwide. As a result, there is a need for considerable research to be done for cancer detection and therapy, and immuno-oncology assays play a significant role in this study.

The discovery, development, and validation of biomarkers demand large capital expenditures. Additionally, diagnostic manufacturers have major financial difficulties as a result of the high drug attrition in clinical trials (with about 30% of medications failing in Phase III). In order for manufacturers to receive regulatory permission for in vitro diagnostics (IVD), Phase III clinical trials that rely on reliable biomarker tests must be successful. The cost of conducting clinical trials and meeting onerous regulatory criteria severely limits innovation and makes it difficult for small businesses to develop biomarkers. As a result, in addition to the high capital expenditures, the low cost-benefit ratio is impeding the expansion of the market for immuno-oncology assays for biomarker identification.

Get Free Sample Copy of This Report: https://www.globalinsightservices.com/request-sample/GIS10299

The key players studied in the market are Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Illumina, Inc. (US), NanoString Technologies, Inc. (US), Sartorius AG (Germany), HTG Molecular Diagnostics, Inc. (US), QIAGEN N.V. (Netherlands), Merck Millipore (US), PerkinElmer, Inc. (US), Abbott Laboratories, Inc. (US), Guardant Health, Inc. (US), and bioMérieux SA (France) among others.

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1–833–761–1700

[vynzresearchindia]

Global Immunoassay Market Size, Share, Demand and Growth Forecast to 2030 | VynZ Research

The Global Immunoassay Market size will reach USD 31.9 Billion by 2030 and is expected to develop at a CAGR of 7.1% during the forecast period (2022-2030), according to VynZ Research. For the forecast year 2022-2030, as well as the historical period 2018-2021, the Global Immunoassay Market has been studied.

The research report provides a comprehensive and insightful examination of the Global Immunoassay Market and includes market analysis on segmentation, dynamics, competition, and regional development. It considers the Global Immunoassay Market's CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, pricing, and other significant parameters. The forecasts in the report are based on well-established research methodology and assumptions.

Explore the recent findings of the Global Immunoassay Market by purchasing a single user PDF@ https://www.vynzresearch.com/healthcare/immunoassay-market/request-sample

Individual strategies were examined in the Global Immunoassay Market study, followed by business profiles of Global Immunoassay Market providers. The study includes an 'Industry Landscape' section that provides readers with a comprehensive view and firms’ market share analysis of major industry players in the Global Immunoassay Market.

Most of the major players in the Global Immunoassay Market are profiled in the report. The strengths and weaknesses, business developments, recent innovations, mergers and acquisitions, expansion plans, global footprint, market presence, and product portfolios of key market competitors are all covered in the company profiling section.

The following are some of the major and developing players in the Global Immunoassay Market:

·         Roche

·         Agilent Technologies

·         Abbott Laboratories

·         Thermo Fisher Scientific

·         Siemens

·         QIAGEN

·         Danaher

·         Ortho Clinical Diagnostics

·         Sysmex

·         Bio-Rad Laboratories

·         BioMérieux

·         Becton

·         Dickinson & Company

·         Mindray

Breakdown of The Segments:

The Global Immunoassay Market is segmented by Product and Service, Platform, Technology, Specimen Type, Application, End-User, and Geography in this study. This segmentation aids executives in planning their products and budgets depending on each segment's expected growth rates.

Product & Services Insight and Forecast 2022-2030

·         Analyzers

·         Reagents & Kit

·         Software

·         Services

Platform Insight and Forecast 2022-2030

·         Chemiluminescence

·         Colorimetric

·         Fluorescence

·         Radioimmunoassays

·         Others

Technology Insight and Forecast 2022-2030

·         Enzyme-Linked Immunosorbent Assays,

·         Enzyme-Linked Immunospot

·         Immuno-PCR

·         Rapid Tests

·         Western Blotting

·         Others

Specimen Type Insight and Forecast 2022-2030

·         Blood

·         Urine

·         Saliva

·         Others

Application Insight and Forecast 2022-2030

·         Infectious Diseases

·         Oncology

·         Cardiology

·         Autoimmune Disorders

·         Neonatal Screening

·         Endocrinology

·         Bone & Mineral Disorders

·         Hematology & Blood Screening

·         Toxicology

·         Others

End User Insight and Forecast 2022-2030

·         Hospitals

·         Blood Banks

·         Clinical Laboratories

·         Pharmaceutical and Biotechnology Companies & CROs

·         Research & Academic Laboratories

·         Others

Geographical Viewpoint:

The research overview provides the major industry trend and the global market's predicted volume based on the regional analysis. The elements that have driven and hampered the market's expansion are also mentioned in this market research analysis. The study is also equipped with the most advanced and effective techniques for gathering, recording, estimating, and evaluating market data.

FAQ

1.      Who are the most dominant players in the global market, and what elements are assisting them in gaining a competitive advantage?

2.      What are the strategies adopted by the key industry players to gain traction in the industry?

3.      By the end of the forecast period, what will the market size and growth rate?

4.      What are the biggest Global Immunoassay Market trends that are influencing market growth?

5.      In the global market, which segment had the biggest revenue share?

Explore More Reports by VynZ Research:

Global Patient Monitoring Device Market – Analysis and Forecast 2022-2030

Global Hernia Repair Market – Analysis and Forecast 2022-2030

Global Diagnostic Imaging Market – Analysis and Forecast 2022-2030

Global Point of Care/Rapid Diagnostic Market – Analysis and Forecast 2022-2030

About VynZ Research

VynZ Research is a global market research firm offering research, analytics, and consulting services on business strategies. VynZ have a recognized trajectory record and our research database is used by many renowned companies and institutions in the world to strategize and revolutionize business opportunities. The company focuses on providing valuable insights on various technology verticals such as Chemicals, Automotive, Transportation, Energy, Consumer Durables, Healthcare, ICT and other emerging technologies.

[healthcareindustrynews]

Immuno Oncology Assays Market worth $7.9 billion by 2026

The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4 billion in 2021, at a CAGR of 12.5%.

[marketresearch-articles]

Immunoassay Reagents and Devices Market Size, Exclusive Research Report by The Insight Partners

Immunoassay Reagents and Devices Market is grow at a CAGR 4.9% in the forecast 2021 to 2028.

Immunoassay Reagents and Devices Market Scope and Size

·        On the basis of product, the immunoassay reagents and devices market is segmented into reagents & kits and analyzers. In 2021, reagents & kits segment is dominating due to its higher usage in drug development as well as in disease detection.

·        On the basis of platform, the immunoassay reagents and devices market is segmented into chemiluminescence immunoassays, fluorescence immunoassays, enzyme immunoassay, radioimmunoassays and others. In 2021, enzyme immunoassay segment is dominating the market because of its advantages such as ease in performing test, accurate result and many others.

·        On the basis of technique, the immunoassay reagents and devices market is segmented into enzyme-linked immunosorbent assays, rapid tests, enzyme-linked immunospot, western blotting, immuno-PCR and other techniques. In 2021, enzyme-linked immunosorbent assays segment is dominating because it is highly sensitive, simple to perform, offer accurate result for any disease detection or in any drug development.

·        On the basis of specimen type, the immunoassay reagents and devices market is segmented into saliva, urine, blood and others. In 2021, blood segment is dominating the market because antigen can be easily detected from the blood.

·        On the basis of application, the immunoassay reagents and devices market is segmented into infectious diseases, oncology and endocrinology, bone & mineral disorders, cardiology, hematology & blood screening, autoimmune disorders, toxicology, neonatal screening and other applications. In 2021, oncology and endocrinology segment is dominating because of high incidence rate worldwide which can be detected easily with the use of immunoassays.

Get the sample copy of Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-immunoassay-reagents-and-devices-market

Global Immunoassay Reagents and Devices Market Country Level Analysis

Global immunoassay reagents and devices market is analyzed and market size information is provided by the country, product, platform, technique, specimen type, application and end user as referenced above.

 The countries covered in the global immunoassay reagents and devices market report are the U.S., Canada, Mexico, Germany, Italy, France, U.K., Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, rest of Europe, China, Japan, India, Australia, Singapore, Indonesia, Thailand, South Korea, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, South Africa, Egypt, UAE, Israel and rest of Middle East and Africa.

Immunoassay Reagents and Devices Market research report indicates that the global Immunoassay Reagents and Devices Market is expected to surge at a steady rate in the coming years. The report provides a comprehensive review of the global market. Analysts have identified the key drivers and restraints in the overall market. The historical milestones achieved by the global market and emerging trends have also been studied in this report. Adopting such market research report is becoming very essential for the businesses as it supports with the better decision making, revenue generation, prioritizing market goals and profitable business.

 The report is objective in nature but includes valuable comments by subject-matter experts. The Immunoassay Reagents and Devices Market research report authenticates and affirms the findings listed by the research analysts. The investigative approach of the research report allows the readers to get a detailed understanding of the finest nuances affecting the market dynamics. This report opens a discussion about the changing economy, governing policies, and political shifts that are expected to shape the market. Moreover, the report assists you in figuring out brand awareness, market landscape, possible future issues, industry trends and customer behaviour which ultimately leads to refined business strategies.

MAJOR TOC OF THE REPORT

Chapter One: Immunoassay Reagents and Devices Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three : Immunoassay Reagents and Devices Market Competition, by Players

Chapter Four: Global Immunoassay Reagents and Devices Market Market Size by Regions

Chapter Five: North Immunoassay Reagents and Devices Market by Countries

Chapter Six: Europe Immunoassay Reagents and Devices Market Revenue by Countries

Chapter Seven: Asia-Pacific Immunoassay Reagents and Devices Market Revenue by Countries

Chapter Eight: South Automotive Immunoassay Reagents and Devices Market Revenue by Countries

Chapter Nine: Middle East and Immunoassay Reagents and Devices Market Revenue Equipment by Countries

Chapter Ten: Global Immunoassay Reagents and Devices Market Segment by Type

Chapter Eleven: Global Immunoassay Reagents and Devices Market by Application

Get TOC Details:   https://www.databridgemarketresearch.com/toc/?dbmr=global-immunoassay-reagents-and-devices-market

major companies dealing in the global immunoassay reagents and devices market report are F. Hoffmann-La Roche Ltd, Siemens, Randox Laboratories Ltd., Abbott, Bio-Rad Laboratories, Inc., Merck KGaA, Beckman Coulter, Inc. (a subsidiary of Danaher), Sysmex Corporation, bioMérieux SA, Thermo Fisher Scientific, Inc., BD, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., DiaSorin S.p.A, Ortho Clinical Diagnostics, QIAGEN, Quidel Corporation, BioCheck, Inc., Bio-Techne, PerkinElmer Inc., Agilent Technologies, Inc., Luminex Corporation, MESO SCALE DIAGNOSTICS, LLC among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Access Full Report   https://www.databridgemarketresearch.com/reports/global-immunoassay-reagents-and-devices-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Browse Related Reports@

Medical Waste Management Market

Yeast Protein Expression Service Market

[healtcare]

Global Haematology and Flow Cytometry Market

Global Haematology and Flow Cytometry Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.

Global Haematology and Flow Cytometry Market Dynamics:

Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells. Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives. ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth. The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays. Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years. To know about the Research Methodology :- Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period. This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.

[jane2000doeaka]

Global Immuno Oncology Assays market was valued at around USD 4.4 billion in 2021 and is expected to grow with the CAGR of 16.5% during forecast period 2021-2027.